Confused about IBC requirements for mRNA clinical trials? Uncertainty around when review is required can delay study startup and introduce compliance risk for sites, sponsors, and CROs.

This white paper explains how NIH Guidelines apply to mRNA-based investigational products, including the underlying science, manufacturing approaches, and regulatory triggers for IBC oversight. You’ll walk away with clear, practical guidance to determine when IBC review is needed and how to ensure compliance while keeping your study moving forward.

Download the white paper.